Product Information
ERYTHROMYCIN DR 250 MG CAP is a generic product labeled by Dr. Reddy's Laboratories Inc., priced at $5.9600 per EA under NDC 75907007601. Its NADAC has been published 102 times since Oct 23, 2024.
FDA first approved this application before 1982. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
250 mg/1
Manufacturer
Dr. Reddy's Laboratories Inc.NDC
75907007601
Classification
Generic
Dosage Form
CAPSULE, DELAYED RELEASE PELLETS
Route
ORAL
Effective Date
4/22/2026
Active Ingredients
ERYTHROMYCINApproval Type
Authorized Generic (NDA)
FDA Application
NDA050536FDA Approved
Before 1982
TE Code
AB
On Market Since
9/1/2024
Pharmacological Classes
Price Statistics
The NADAC for ERYTHROMYCIN DR 250 MG CAP has been published 102 times since Oct 23, 2024, and over the history we have for it it has declined 10.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $5.9600 per EA |
|---|---|
| All-time high | $6.6741 (May 14, 2025) |
| All-time low | $5.9600 (Apr 22, 2026) |
| 52-week high | $6.6472 |
| 52-week low | $5.9600 |
| Median price | $6.3775 |
| Average price | $6.3613 |
| Largest weekly change | -5.4% (Apr 22, 2026) |
| Weeks tracked | 102 |
| Tracking since | Oct 23, 2024 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the erythromycin market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Dr. Reddy's Laboratories Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
erythromycin market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Macrolide Antimicrobial class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ERYTHROMYCIN DR 250 MG CAP?
The current National Average Drug Acquisition Cost (NADAC) for ERYTHROMYCIN DR 250 MG CAP, manufactured by Dr. Reddy's Laboratories Inc., is $5.9600 per EA (NDC 75907007601), effective Sep 30, 2026.
How has the price of ERYTHROMYCIN DR 250 MG CAP changed over time?
Over the history we have for it, the NADAC for ERYTHROMYCIN DR 250 MG CAP has declined 10.7%. It has been tracked across 102 weekly CMS publications since Oct 23, 2024.
What are the highest and lowest recorded NADAC prices for ERYTHROMYCIN DR 250 MG CAP?
Since Oct 23, 2024, the NADAC for ERYTHROMYCIN DR 250 MG CAP has ranged from a low of $5.9600 (Apr 22, 2026) to a high of $6.6741 (May 14, 2025), with a median of $6.3775 per EA.
Are there cheaper alternatives to ERYTHROMYCIN DR 250 MG CAP?
No other NADAC-published product currently shares the active ingredient and strength of ERYTHROMYCIN DR 250 MG CAP in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures ERYTHROMYCIN DR 250 MG CAP?
ERYTHROMYCIN DR 250 MG CAP (NDC 75907007601) is labeled by Dr. Reddy's Laboratories Inc., and CMS classifies it as a generic product.